Immunohistochemical characteristics of breast cancer, increasing the risk of local reccurence after organosaving treatment
https://doi.org/10.17650/1994-4098-2018-14-3-10-14
Abstract
Objective: an immunohistochemical analysis of the characteristics of a recurrent tumor in breast cancer. Materials and methods. The statistical processing of immunohistochemical analysis’ results was performed and the most frequently encountered molecular-genetic subtypes of breast cancer with the development of local relapses were formulated. The analysis used a standard immunohistochemical panel, which is the “gold standard” for diagnostic in Russia today, and includes the expression of receptors for sex hormones (estrogen and progesterone), expression of the human epidermal growth factor HER2/neu receptor gene, and the index of proliferative activity Ki-67. The 2nd stage of the work was the evaluation of the dynamics of changes in the immunohistochemical characteristics of a recurrent tumor in comparison with the primary one. Results and conclusion. The most common local recurrence provides by triple-negative subtype of breast cancer (42 %). The changes in the immunohistochemical characteristics of a recurrent tumor in comparison with the primary one affected only the index of proliferative activity Ki-67 in the direction of its increase by 12 %.
About the Authors
S. M. Demidov
Urals State Medical University, Ministry of Health of Russia; City Clinical Hospital No. 40
Russian Federation
Competing Interests: The authors declare no conflict of interest
Russian Federation
3 Repina St., 620219 Ekaterinburg
189 Volgogradskaya St., 620102 Ekaterinburg
Competing Interests: The authors declare no conflict of interest
D. A. Demidov
Urals State Medical University, Ministry of Health of Russia; City Clinical Hospital No. 40
Russian Federation
Competing Interests: The authors declare no conflict of interest
Russian Federation
3 Repina St., 620219 Ekaterinburg
189 Volgogradskaya St., 620102 Ekaterinburg
Competing Interests: The authors declare no conflict of interest
S. V. Sazonov
Urals State Medical University, Ministry of Health of Russia; Institute of Medical Cell Technologies
Russian Federation
Competing Interests: The authors declare no conflict of interest
Russian Federation
3 Repina St., 620219 Ekaterinburg
22а Karla Marksa St., 620026 Ekaterinburg
Competing Interests: The authors declare no conflict of interest
E. I. Churakova
Urals State Medical University, Ministry of Health of Russia
Russian Federation
3 Repina St., 620219 Ekaterinburg
Competing Interests: The authors declare no conflict of interest
Russian Federation
3 Repina St., 620219 Ekaterinburg
Competing Interests: The authors declare no conflict of interest
References
1. Злокачественные новообразования в России в 2016 году. Под ред. А.Д. Каприна, В.В. Старинской, Г.В. Петрова. Доступно по: http://www.oncology.ru. [Malignant tumors in Russia in 2016. Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Petrov. Available at: http://www.oncology.ru. (In Russ.)].
2. Уйманов В.А., Триголосов А.В., Петровский А.В. и др. Возможность органосохраняющего лечения местных рецидивов рака молочной железы. Опухоли женской репродуктивной системы 2013;(3–4):45–9. [Uimanov V.A., Trigolosov A.V., Petrovskiy A.V. et al. Organ-sparing treatment for local recurrent breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2013;(3–4):45–9. (In Russ.)].
3. Arriagada R., Le M. G., Rochard F. et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave–Roussy Breast Cancer Group. J Clin Oncol 1996;14(5):1558–64. PMID: 8622072. DOI: 10.1200/JCO.1996.14.5.1558.
4. Litiere S., Werutsky G., Fentiman I.S. et al. Breast conserving therapy versus mastectomy for stage I–II breast cancer: 20 year followup of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012;13(4):412–9. PMID: 22373563. DOI: 10.1016/S1470-2045(12)70042-6.
5. Колядина И.В., Поддубная И.В., Франк Г.А. и др. Прогностическое значение возраста больных при раннем раке молочной железы. Современные технологии в медицине 2012;(3):31–5. [Kolyadina I.V., Poddubnaya I.V., Frank G.A. et al. Prognostic value of patient age in early-stage breast cancer. Sovremennye tekhnologii v meditsine = Modern Technologies in Medicine 2012;(3):31–5. (In Russ.)].
6. Семиглазов В.Ф. Рак молочной железы: мультидисциплинарный подход к лечению. Практическая онкология 2015;16(2):49–52. [Semiglazov V.F. Breast cancer: multidisciplinary approach to treatment. Prakticheskaya onkologiya = Practical Oncology 2015;16(2):49–52. (In Russ.)].
7. Демидов С.М., Сазонов С.В., Демидов Д.А. и др. Дополнительные возможности иммуногистохимической диагностики микрометастазов в лимфатические узлы пациенток с ранним раком молочной железы. Уральский медицинский журнал 2014;2(116):51–3. [Demidov S.M., Sazonov S.V., Demidov D.A. et al. Extra opportunities of immunohistochemical diagnostics of lymph node micrometastases in patients with early-stage breast cancer. Uralskiy meditsinskiy zhurnal = Ural Medical Journal 2014;2(116):51–3. (In Russ.)].
8. Никитенко Н.В., Сеньчукова М.А., Томчук О.Н. и др. Морфологическая характеристика и прогностическое значение разных типов сосудов при раке молочной железы. Российский биотерапевтический журнал 2016;(3):15–21. [Nikitenko N.V., Sen’chukova M.A., Tomchuk O.N. et al. Morphological characteristics and prognostic value of different vessels in breast cancer. Rossiyskiy bioterapevticheskiy zhurnal = Russian Biotherapeutic Journal 2016;(3):15–21. (In Russ.)].
9. Палтуев Р.М., Кудайбергенова А.Г., Семиглазов В.Ф., Комяхов А.В. Автоматизированный анализ клеточной плотности при раке молочной железы как дополнительный способ повысить объективность и достоверность прогноза рака молочной желез. Опухоли женской репродуктивной системы 2017;13(3):12–6. [Paltuev R.M., Kudaybergenova A.G., Semiglazov V.F., Komyakhov A.V. Automated analysis of cell density in breast cancer as an additional method to improve objectivity and accuracy of breast cancer prognosis. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2017;13(3):12–6. (In Russ.)].
10. Шашова Е.Е., Кондакова И.В., Слонимская Е.М., Глущенко С.А. Ферменты метаболизма эстрогенов при метастазировании рака молочной железы. Молекулярная медицина 2010;(2): 47–51. [Shashova E.E., Kondakova I.V., Slonimskaya E.M., Gluschenko S.A. Enzymes of estrogen metabolism in metastatic breast cancer. Molekulyarnaya meditsina = Molecular Medicine 2010;(2):47–51. (In Russ.)].
11. Вторушин С.В., Перельмутер В.М., Завьялова М.В., Слонимская Е.М. Синхронное и метахронное развитие локальных рецидивов и отдаленных метастазов у больных с РМЖ. Сибирский онкологический журнал 2011;(2):27–31. [Vtorushin S.V., Perel’- muter V.M., Zavyalova M.V., Slonimskaya E.M. Synchronous and metachronous development of local recurrent tumors and distant metastases in patients with breast cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2011;(2):27–31. (In Russ.)].
12. Bardou V., Arpino G., Elledge R. еt al. Progesterone reseptor status significantly improves outcome prediction over estrogen status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21(10):1973–9. PMID: 12743151. DOI: 10.1200/JCO.2003.09.099.
13. Конышев К.В., Бриллиант А.А., Сазонов С.В. Изменение экспрессии рецепторов к эстрогену клетками карциномы молочной железы при регионарном метастазировании. Вестник уральской медицинской академической науки 2015;2(53):4–6. [Konyshev K.V., Brilliant A.A., Sazonov S.V. Changes in the expression of estrogen receptors by breast cancer cells in patients with regional metastasis. Vestnik Ural’skoy meditsinskoy akademicheskoy nauki = Journal of Ural Medical Academic Science 2015;2(53):4–6. (In Russ.)].
14. Liedtke C., Broglio K., Moulder S. еt al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. J Ann Oncol 2009;20(12):1953–8. PMID: 19596702. DOI: 10.1093/annonc/mdp263.
15. Семиглазов В.Ф., Палтуев Р.М., Семиглазов В.В. и др. Ранний рак молочной железы: прогностическое значение биологических подтипов (анализ кумулятивной базы данных «НИИ онкологии им. Н.Н. Петрова» Минздравсоцразвития). Злокачественные опухоли 2012;(2):12–8. [Semiglazov V.F., Paltuev R.M., Semiglazov V.V. et al. Early-stage breast cancer: prognostic value of biological subtypes (analysis of a cumulative database from the N.N. Petrov Research Institute of Oncology, Ministry of Health of Russia). Zlokachestvennye opukholi = Malignant Tumors 2012;(2):12–8. (In Russ.)].
16. Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли 2016;4(cпецвыпуск 2):97–122. [Stenina M.B., Zhukova L.G., Koroleva I.A. et al. Practical guidelines for pharmacotherapy of invasive breast cancer. Zlokachestvennye opukholi = Malignant Tumors 2016;4(special issue 2):97–122. (In Russ.)].
17. Metzger-Filho O., Sun Z., Viale G. et al. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 2013;31(25): 3083–90.
Review
For citations:
Demidov S.M., Demidov D.A., Sazonov S.V., Churakova E.I. Immunohistochemical characteristics of breast cancer, increasing the risk of local reccurence after organosaving treatment. Tumors of female reproductive system. 2018;14(3):10-14. (In Russ.) https://doi.org/10.17650/1994-4098-2018-14-3-10-14
Views:
2797
Email this article 